The editors of the journal Neurotherapeutics have announced that the journal's July issue is dedicated to 'Novel Therapeutics for Alzheimer's Disease.' Published by Elsevier, Neurotherapeutics is the journal of the American Society of Experimental NeuroTherapeutics (ASENT).
The issue coincides with the 2008 Alzheimer's Association International Conference on Alzheimer's Disease (ICAD), being held at McCormick Place, Chicago, July 26-31, 2008. Dr Rudolph E. Tanzi of the Massachusetts General Institute for Neurodegenerative Disease and Massachusetts General Hospital is the Guest Editor.
This special issue enlists several experts in the field to review new therapeutics currently under development for the treatment and prevention of the Alzheimer's Disease. The eleven papers in the issue highlight promising therapeutic targets for the disease, providing an update on efforts to develop treatments. The lead article in the issue looks at techniques for measuring the effects of disease-modifying therapies on cerebral Aβ levels - including the key question of whether they correlate with cognitive performance. Clinical trials aimed at all of these therapeutic targets are underway.
In his editorial, Dr Tanzi expresses 'cautious optimism and high hopes' that these trials may lead to new therapeutic approaches to Alzheimer's disease. The full text of a paper on the metal hypothesis, co-authored by Dr. Tanzi, has been made available free of charge at http://www.neurotherapeutics.org/content/editorschoice. Subscribers and ASENT members can access the full content of each issue of Neurotherapeutics at the journal website at www.neurotherapeutics.org. Institutional subscribers can access the journal through ScienceDirect.
